CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: primary tumor</title> <meta name="description" content="Search results for: primary tumor"> <meta name="keywords" content="primary tumor"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="primary tumor" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="primary tumor"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 5236</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: primary tumor</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5236</span> On Consolidated Predictive Model of the Natural History of Breast Cancer Considering Primary Tumor and Primary Distant Metastases Growth</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ella%20Tyuryumina">Ella Tyuryumina</a>, <a href="https://publications.waset.org/abstracts/search?q=Alexey%20Neznanov"> Alexey Neznanov</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Finding algorithms to predict the growth of tumors has piqued the interest of researchers ever since the early days of cancer research. A number of studies were carried out as an attempt to obtain reliable data on the natural history of breast cancer growth. Mathematical modeling can play a very important role in the prognosis of tumor process of breast cancer. However, mathematical models describe primary tumor growth and metastases growth separately. Consequently, we propose a mathematical growth model for primary tumor and primary metastases which may help to improve predicting accuracy of breast cancer progression using an original mathematical model referred to CoM-IV and corresponding software. We are interested in: 1) modelling the whole natural history of primary tumor and primary metastases; 2) developing adequate and precise CoM-IV which reflects relations between PT and MTS; 3) analyzing the CoM-IV scope of application; 4) implementing the model as a software tool. The CoM-IV is based on exponential tumor growth model and consists of a system of determinate nonlinear and linear equations; corresponds to TNM classification. It allows to calculate different growth periods of primary tumor and primary metastases: 1) ‘non-visible period’ for primary tumor; 2) ‘non-visible period’ for primary metastases; 3) ‘visible period’ for primary metastases. The new predictive tool: 1) is a solid foundation to develop future studies of breast cancer models; 2) does not require any expensive diagnostic tests; 3) is the first predictor which makes forecast using only current patient data, the others are based on the additional statistical data. Thus, the CoM-IV model and predictive software: a) detect different growth periods of primary tumor and primary metastases; b) make forecast of the period of primary metastases appearance; c) have higher average prediction accuracy than the other tools; d) can improve forecasts on survival of BC and facilitate optimization of diagnostic tests. The following are calculated by CoM-IV: the number of doublings for ‘nonvisible’ and ‘visible’ growth period of primary metastases; tumor volume doubling time (days) for ‘nonvisible’ and ‘visible’ growth period of primary metastases. The CoM-IV enables, for the first time, to predict the whole natural history of primary tumor and primary metastases growth on each stage (pT1, pT2, pT3, pT4) relying only on primary tumor sizes. Summarizing: a) CoM-IV describes correctly primary tumor and primary distant metastases growth of IV (T1-4N0-3M1) stage with (N1-3) or without regional metastases in lymph nodes (N0); b) facilitates the understanding of the appearance period and manifestation of primary metastases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=exponential%20growth%20model" title=" exponential growth model"> exponential growth model</a>, <a href="https://publications.waset.org/abstracts/search?q=mathematical%20modelling" title=" mathematical modelling"> mathematical modelling</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20metastases" title=" primary metastases"> primary metastases</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20tumor" title=" primary tumor"> primary tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=survival" title=" survival"> survival</a> </p> <a href="https://publications.waset.org/abstracts/65180/on-consolidated-predictive-model-of-the-natural-history-of-breast-cancer-considering-primary-tumor-and-primary-distant-metastases-growth" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/65180.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5235</span> Predictive Value of Primary Tumor Depth for Cervical Lymphadenopathy in Squamous Cell Carcinoma of Buccal Mucosa</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zohra%20Salim">Zohra Salim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: To access the relationship of primary tumor thickness with cervical lymphadenopathy in squamous cell carcinoma of buccal mucosa. Methodology: A cross-sectional observational study was carried out on 80 Patients with biopsy-proven oral squamous cell carcinoma of buccal mucosa at Dow University of Health Sciences. All the study participants were treated with wide local excision of the primary tumor with elective neck dissection. Patients with prior head and neck malignancy or those with prior radiotherapy or chemotherapy were excluded from the study. Data was entered and analyzed on SPSS 21. Chi-squared test with 95% C.I and 80% power of the test was used to evaluate the relationship of tumor depth with cervical lymph nodes. Results: 50 participants were male, and 30 patients were female. 30 patients were in the age range of 20-40 years, 36 patients in the range of 40-60 years, while 14 patients were beyond age 60 years. Tumor size ranged from 0.3cm to 5cm with a mean of 2.03cm. Tumor depth ranged from 0.2cm to 5cm. 20% of the participants reported with tumor depth greater than 2.5cm, while 80% of patients reported with tumor depth less than 2.5cm. Out of 80 patients, 27 reported with negative lymph nodes, while 53 patients reported with positive lymph nodes. Conclusion: Our study concludes that relationship exists between the depth of primary tumor and cervical lymphadenopathy in squamous cell carcinoma of buccal mucosa. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=squamous%20cell%20carcinoma" title="squamous cell carcinoma">squamous cell carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20depth" title=" tumor depth"> tumor depth</a>, <a href="https://publications.waset.org/abstracts/search?q=cervical%20lymphadenopathy" title=" cervical lymphadenopathy"> cervical lymphadenopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=buccal%20mucosa" title=" buccal mucosa"> buccal mucosa</a> </p> <a href="https://publications.waset.org/abstracts/85223/predictive-value-of-primary-tumor-depth-for-cervical-lymphadenopathy-in-squamous-cell-carcinoma-of-buccal-mucosa" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/85223.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">237</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5234</span> On Consolidated Predictive Model of the Natural History of Breast Cancer Considering Primary Tumor and Secondary Distant Metastases Growth in Patients with Lymph Nodes Metastases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ella%20Tyuryumina">Ella Tyuryumina</a>, <a href="https://publications.waset.org/abstracts/search?q=Alexey%20Neznanov"> Alexey Neznanov</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This paper is devoted to mathematical modelling of the progression and stages of breast cancer. We propose Consolidated mathematical growth model of primary tumor and secondary distant metastases growth in patients with lymph nodes metastases (CoM-III) as a new research tool. We are interested in: 1) modelling the whole natural history of primary tumor and secondary distant metastases growth in patients with lymph nodes metastases; 2) developing adequate and precise CoM-III which reflects relations between primary tumor and secondary distant metastases; 3) analyzing the CoM-III scope of application; 4) implementing the model as a software tool. Firstly, the CoM-III includes exponential tumor growth model as a system of determinate nonlinear and linear equations. Secondly, mathematical model corresponds to TNM classification. It allows to calculate different growth periods of primary tumor and secondary distant metastases growth in patients with lymph nodes metastases: 1) ‘non-visible period’ for primary tumor; 2) ‘non-visible period’ for secondary distant metastases growth in patients with lymph nodes metastases; 3) ‘visible period’ for secondary distant metastases growth in patients with lymph nodes metastases. The new predictive tool: 1) is a solid foundation to develop future studies of breast cancer models; 2) does not require any expensive diagnostic tests; 3) is the first predictor which makes forecast using only current patient data, the others are based on the additional statistical data. Thus, the CoM-III model and predictive software: a) detect different growth periods of primary tumor and secondary distant metastases growth in patients with lymph nodes metastases; b) make forecast of the period of the distant metastases appearance in patients with lymph nodes metastases; c) have higher average prediction accuracy than the other tools; d) can improve forecasts on survival of breast cancer and facilitate optimization of diagnostic tests. The following are calculated by CoM-III: the number of doublings for ‘non-visible’ and ‘visible’ growth period of secondary distant metastases; tumor volume doubling time (days) for ‘non-visible’ and ‘visible’ growth period of secondary distant metastases. The CoM-III enables, for the first time, to predict the whole natural history of primary tumor and secondary distant metastases growth on each stage (pT1, pT2, pT3, pT4) relying only on primary tumor sizes. Summarizing: a) CoM-III describes correctly primary tumor and secondary distant metastases growth of IA, IIA, IIB, IIIB (T1-4N1-3M0) stages in patients with lymph nodes metastases (N1-3); b) facilitates the understanding of the appearance period and inception of secondary distant metastases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=exponential%20growth%20model" title=" exponential growth model"> exponential growth model</a>, <a href="https://publications.waset.org/abstracts/search?q=mathematical%20model" title=" mathematical model"> mathematical model</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20tumor" title=" primary tumor"> primary tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=secondary%20metastases" title=" secondary metastases"> secondary metastases</a>, <a href="https://publications.waset.org/abstracts/search?q=survival" title=" survival"> survival</a> </p> <a href="https://publications.waset.org/abstracts/65181/on-consolidated-predictive-model-of-the-natural-history-of-breast-cancer-considering-primary-tumor-and-secondary-distant-metastases-growth-in-patients-with-lymph-nodes-metastases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/65181.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">302</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5233</span> Consolidated Predictive Model of the Natural History of Breast Cancer Considering Primary Tumor and Secondary Distant Metastases Growth</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ella%20Tyuryumina">Ella Tyuryumina</a>, <a href="https://publications.waset.org/abstracts/search?q=Alexey%20Neznanov"> Alexey Neznanov</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This study is an attempt to obtain reliable data on the natural history of breast cancer growth. We analyze the opportunities for using classical mathematical models (exponential and logistic tumor growth models, Gompertz and von Bertalanffy tumor growth models) to try to describe growth of the primary tumor and the secondary distant metastases of human breast cancer. The research aim is to improve predicting accuracy of breast cancer progression using an original mathematical model referred to CoMPaS and corresponding software. We are interested in: 1) modelling the whole natural history of the primary tumor and the secondary distant metastases; 2) developing adequate and precise CoMPaS which reflects relations between the primary tumor and the secondary distant metastases; 3) analyzing the CoMPaS scope of application; 4) implementing the model as a software tool. The foundation of the CoMPaS is the exponential tumor growth model, which is described by determinate nonlinear and linear equations. The CoMPaS corresponds to TNM classification. It allows to calculate different growth periods of the primary tumor and the secondary distant metastases: 1) ‘non-visible period’ for the primary tumor; 2) ‘non-visible period’ for the secondary distant metastases; 3) ‘visible period’ for the secondary distant metastases. The CoMPaS is validated on clinical data of 10-years and 15-years survival depending on the tumor stage and diameter of the primary tumor. The new predictive tool: 1) is a solid foundation to develop future studies of breast cancer growth models; 2) does not require any expensive diagnostic tests; 3) is the first predictor which makes forecast using only current patient data, the others are based on the additional statistical data. The CoMPaS model and predictive software: a) fit to clinical trials data; b) detect different growth periods of the primary tumor and the secondary distant metastases; c) make forecast of the period of the secondary distant metastases appearance; d) have higher average prediction accuracy than the other tools; e) can improve forecasts on survival of breast cancer and facilitate optimization of diagnostic tests. The following are calculated by CoMPaS: the number of doublings for ‘non-visible’ and ‘visible’ growth period of the secondary distant metastases; tumor volume doubling time (days) for ‘non-visible’ and ‘visible’ growth period of the secondary distant metastases. The CoMPaS enables, for the first time, to predict ‘whole natural history’ of the primary tumor and the secondary distant metastases growth on each stage (pT1, pT2, pT3, pT4) relying only on the primary tumor sizes. Summarizing: a) CoMPaS describes correctly the primary tumor growth of IA, IIA, IIB, IIIB (T1-4N0M0) stages without metastases in lymph nodes (N0); b) facilitates the understanding of the appearance period and inception of the secondary distant metastases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=exponential%20growth%20model" title=" exponential growth model"> exponential growth model</a>, <a href="https://publications.waset.org/abstracts/search?q=mathematical%20model" title=" mathematical model"> mathematical model</a>, <a href="https://publications.waset.org/abstracts/search?q=metastases%20in%20lymph%20nodes" title=" metastases in lymph nodes"> metastases in lymph nodes</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20tumor" title=" primary tumor"> primary tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=survival" title=" survival"> survival</a> </p> <a href="https://publications.waset.org/abstracts/65182/consolidated-predictive-model-of-the-natural-history-of-breast-cancer-considering-primary-tumor-and-secondary-distant-metastases-growth" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/65182.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">341</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5232</span> Metastatic Ovarian Tumor Discovered Accidentally during Cesarean Section in a 34 Year Old Woman: A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ghada%20E.%20Esheba">Ghada E. Esheba</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghufran%20Kheshaifaty"> Ghufran Kheshaifaty</a>, <a href="https://publications.waset.org/abstracts/search?q=Kholoud%20%20Al-Harbi"> Kholoud Al-Harbi</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafa%27a%20Al-Harbi"> Wafa'a Al-Harbi</a>, <a href="https://publications.waset.org/abstracts/search?q=Ala%27a%20Al-Orabi"> Ala'a Al-Orabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Moayad%20Turkistani"> Moayad Turkistani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Krukenberg tumor is a rare metastatic ovarian carcinoma that usually occurs in female between 30 - 40 year old and rarely seen after menopause. Stomach is the most common primary site. Histopathological features of krukenberg tumors appear as diffuse stromal proliferation, mucus-production, and numerous signet-cells and these tumors spread mostly by lymphatic route. Treatment and prognostic factors are not well established. This study describes a 34 year old female with a unilateral ovarian mass discovered accidentally during cesarean section delivery and it was misdiagnosed as luteoma of pregnancy, but histopathological examination showed a diffuse infiltration of the ovary and omentum by signet ring cells. These findings were not correlated with luteoma of pregnancy or any other types of primary ovarian tumors like surface epithelial tumor, sex cord stromal tumor or germ cell tumor. However, after the analysis of immunohistochemical results (negative CK7, positive CK20 and CDX-2), the finding was the diagnostic of metastatic krukenberg tumor. Two weeks later, the patient was evaluated and a large gastric tumor was found in her stomach and she underwent gastrectomy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=CK7" title="CK7">CK7</a>, <a href="https://publications.waset.org/abstracts/search?q=CK20" title=" CK20"> CK20</a>, <a href="https://publications.waset.org/abstracts/search?q=CDX-2" title=" CDX-2"> CDX-2</a>, <a href="https://publications.waset.org/abstracts/search?q=Krukenburg%20tumor" title=" Krukenburg tumor"> Krukenburg tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=metastatic%20ovarian%20tumor" title=" metastatic ovarian tumor"> metastatic ovarian tumor</a> </p> <a href="https://publications.waset.org/abstracts/59354/metastatic-ovarian-tumor-discovered-accidentally-during-cesarean-section-in-a-34-year-old-woman-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/59354.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">315</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5231</span> WT1 Expression in Ovarian Malignant Surface Epithelial Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahmoodreza%20Tahamtan">Mahmoodreza Tahamtan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Malignant surface epithelial ovarian tumors(SEOT) account for approximately 90% of primary ovarian cancer. We evaluate the immunohistochemical expression of WT1 protein among different histologic subtypes of SEOT. Immunohistochemistry for WT1 was done on 35 serous cystadenocarcinomas, 9 borderline serous tumors. A tumor was considered negative if < 1% of tumor cells were stained.Positive reactions were graded as follows:1+,1%-24%; 2+,25%-49%; 3+,50%-74%; 4+,75%-100%. Of the 35 cases of ovarian serous cystadenocarcinoma 30(85.7%)were diffusely positive(3+,4+),4 showed reactivity of < 50% of the tumor cells(1+,2+) and one were negative. All 9 borderline serous tumors showed immunoreactivity with WT1. WT1 is a good marker to distinguish primary ovarian serous carcinomas from other surface epithelial tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=WT1" title="WT1">WT1</a>, <a href="https://publications.waset.org/abstracts/search?q=ovary" title=" ovary"> ovary</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a>, <a href="https://publications.waset.org/abstracts/search?q=epithelial%20tumors" title=" epithelial tumors"> epithelial tumors</a> </p> <a href="https://publications.waset.org/abstracts/160272/wt1-expression-in-ovarian-malignant-surface-epithelial-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/160272.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">102</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5230</span> WT1 Exprassion in Malignant Surface Epithelial Ovarian Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahmoodreza%20Tahamtan">Mahmoodreza Tahamtan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Malignant surface epithelial ovarian tumors (SEOT) account for approximately 90% of primary ovarian cancer. Wilms tumor gene (WT1) product was defined as a tumor suppressor gene, but today it is considered capable of performing oncogenic functions. There seems to be differences in WT1 expression patterns among SEOT subtypes. We evaluate the immunohistochemical expression of WT1 protein among different histologic subtypes of SEOT. Materials and Methods: Immunohistochemistry for WT1 was done on 35 serous cystadenocarcinomas, 9 borderline serous tumors, 3 mucinous cystadenocarcinomas, 10 borderline mucinous tumors, 7 endometrioid ovarian carcinomas, 3 clear cell carcinomas, 1 malignant Brenner tumor, 2 metastatic adenocarcinomas, and 6 endometrial adenocarcinomas. A tumor was considered negative if < 1% of tumor cells were stained.Positive reactions were graded as follows:1+,1%-24%; 2+,25%-49%; 3+,50%-74%; 4+,75%-100%. Results: Of the 35 cases of ovarian serous cystadenocarcinoma, 30(85.7%) were diffusely positive (3+,4+),4 showed reactivity of < 50% of the tumor cells (1+,2+), and one were negative. All 9 borderline serous tumors showed immunoreactivity with WT1. All the mucinous tumors(n:13), endometrioid carcinomas (n: 7), clear cell carcinomas (n: 3), metastatic adenocarcinomas (n: 2) and primary endometrial carcinomas (n:6) were negative. The single malignant Brenner tumor showed a positive reaction for WT1(4+) Conclusion: WT1 is a good marker to distinguish primary ovarian serous carcinomas from other surface epithelial tumors (especially endometrioid subtype) and metastatic carcinomas (especially endometrial serous carcinoma), other than malignant mesothelioma. We cannot rely to the degree of expression inorder to separate high grade borderline serous tumors from low grade ones. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=WT1" title="WT1">WT1</a>, <a href="https://publications.waset.org/abstracts/search?q=ovary" title=" ovary"> ovary</a>, <a href="https://publications.waset.org/abstracts/search?q=epithelial%20tumors" title=" epithelial tumors"> epithelial tumors</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a> </p> <a href="https://publications.waset.org/abstracts/159905/wt1-exprassion-in-malignant-surface-epithelial-ovarian-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/159905.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">103</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5229</span> The Epigenetic Background Depended Treatment Planning for Glioblastoma Multiforme</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rasime%20Kalkan">Rasime Kalkan</a>, <a href="https://publications.waset.org/abstracts/search?q=Emine%20Ikbal%20Atli"> Emine Ikbal Atli</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Arslanta%C5%9F"> Ali Arslantaş</a>, <a href="https://publications.waset.org/abstracts/search?q=Muhsin%20%C3%96zdemir"> Muhsin Özdemir</a>, <a href="https://publications.waset.org/abstracts/search?q=Sevilhan%20Artan"> Sevilhan Artan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Glioblastoma (WHO grade IV), is the malignant form of brain tumor, the genetic background of the GBM is highly variable. The tumor mass of a GBM is multilayered and every tumor layer shows distinct characteristics with a different cell population. The treatment planning of GBM should be focused on the tumor genetic characteristics. We screened primary glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and IDH1 mutation correlated them with clinical data and treatment. There was no correlation between MGMT-promoter methylation and overall survival. The overall survival time of the patients with methylated RARβ was statically (OS;p<0,05) significance between the patients who were treated with chemotherapy and radiotherapy. Here we showed the status of IDH1 gene associatied with younger age. We demonstrated that the together with MGMT gene the RARβ gene should be used as a potantial treatment decision marker for GBMs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=RAR%CE%B2" title="RARβ">RARβ</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20glioblastoma%20multiforme" title=" primary glioblastoma multiforme"> primary glioblastoma multiforme</a>, <a href="https://publications.waset.org/abstracts/search?q=methylation" title=" methylation"> methylation</a>, <a href="https://publications.waset.org/abstracts/search?q=MGMT" title=" MGMT"> MGMT</a> </p> <a href="https://publications.waset.org/abstracts/66871/the-epigenetic-background-depended-treatment-planning-for-glioblastoma-multiforme" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/66871.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">344</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5228</span> PCR Based DNA Analysis in Detecting P53 Mutation in Human Breast Cancer (MDA-468)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Debbarma%20Asis">Debbarma Asis</a>, <a href="https://publications.waset.org/abstracts/search?q=Guha%20Chandan"> Guha Chandan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor Protein-53 (P53) is one of the tumor suppressor proteins. P53 regulates the cell cycle that conserves stability by preventing genome mutation. It is named so as it runs as 53-kilodalton (kDa) protein on Polyacrylamide gel electrophoresis although the actual mass is 43.7 kDa. Experimental evidence has indicated that P53 cancer mutants loses tumor suppression activity and subsequently gain oncogenic activities to promote tumourigenesis. Tumor-specific DNA has recently been detected in the plasma of breast cancer patients. Detection of tumor-specific genetic materials in cancer patients may provide a unique and valuable tumor marker for diagnosis and prognosis. Commercially available MDA-468 breast cancer cell line was used for the proposed study. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=tumor%20protein%20%28P53%29" title="tumor protein (P53)">tumor protein (P53)</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20mutants" title=" cancer mutants"> cancer mutants</a>, <a href="https://publications.waset.org/abstracts/search?q=MDA-468" title=" MDA-468"> MDA-468</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20suppressor%20gene" title=" tumor suppressor gene"> tumor suppressor gene</a> </p> <a href="https://publications.waset.org/abstracts/43690/pcr-based-dna-analysis-in-detecting-p53-mutation-in-human-breast-cancer-mda-468" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43690.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">478</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5227</span> Primary Melanocytic Tumors of the Central Nervous System: A Clinico-Pathological Study of Seven Cases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sushila%20Jaiswal">Sushila Jaiswal</a>, <a href="https://publications.waset.org/abstracts/search?q=Awadhesh%20Kumar%20Jaiswal"> Awadhesh Kumar Jaiswal</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Primary melanocytic tumors of the central nervous system (CNS) are uncommon lesions and arise from the melanocytes located within the leptomeninges. Aim and objective: The aim of the study was to evaluate the clinical details, histomorphology of the primary melanocytic tumor of CNS. Method: The study was performed by the retrospective review of the case records of the primary melanocytic tumors of CNS diagnosed in our department. The formalin-fixed, paraffin embedded tissue blocks and tissue sections were retrieved and reviewed. Results: Seven cases (6 males, 1 female; age range- 16-40 years; mean age- 27 years) of primary melanocytic tumors of CNS were retrieved over last seven years. The tumor was intracranial (n=5; frontal – 1 case, parietal – 1 case, cerebello-pontine angle- 1 case, occipital -1 case, foramen magnum-1 case) and intra spinal (n=2; cervical – 2 cases). All patients presented with the neurological deficits related to the location of the tumor. Four cases were malignant melanoma; two were melanocytoma of intermediate grade and remaining one was melanocytoma. On histopathology, melanocytoma and melanoma both displayed sheets of well-differentiated melanocytes having round to oval nuclei with finely dispersed chromatin, occasional single eosinophilic nucleoli and a moderate amount of cytoplasm with abundant granular melanin pigment. The absence of mitosis and macronucleoli was noticed in melanocytoma while melanoma showed frequent mitosis and macronucleoli. On immunohistochemistry, both showed diffuse strong HMB45 and S-100 immunopositivity. Conclusion: Primary melanocytic tumors of CNS are rare and predominantly seen in males. It is important to differentiate melanoma from melanocytoma as prognosis of later is good. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=melanocytoma" title="melanocytoma">melanocytoma</a>, <a href="https://publications.waset.org/abstracts/search?q=melanoma" title=" melanoma"> melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=brain%20tumor" title=" brain tumor"> brain tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=melanin" title=" melanin"> melanin</a> </p> <a href="https://publications.waset.org/abstracts/54456/primary-melanocytic-tumors-of-the-central-nervous-system-a-clinico-pathological-study-of-seven-cases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/54456.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">233</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5226</span> Ultra Wideband Breast Cancer Detection by Using SAR for Indication the Tumor Location</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Wittawat%20Wasusathien">Wittawat Wasusathien</a>, <a href="https://publications.waset.org/abstracts/search?q=Samran%20Santalunai"> Samran Santalunai</a>, <a href="https://publications.waset.org/abstracts/search?q=Thanaset%20Thosdeekoraphat"> Thanaset Thosdeekoraphat</a>, <a href="https://publications.waset.org/abstracts/search?q=Chanchai%20Thongsopa"> Chanchai Thongsopa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This paper presents breast cancer detection by observing the specific absorption rate (SAR) intensity for identification tumor location, the tumor is identified in coordinates (x,y,z) system. We examined the frequency between 4-8 GHz to look for the most appropriate frequency. Results are simulated in frequency 4-8 GHz, the model overview include normal breast with 50 mm radian, 5 mm diameter of tumor, and ultra wideband (UWB) bowtie antenna. The models are created and simulated in CST Microwave Studio. For this simulation, we changed antenna to 5 location around the breast, the tumor can be detected when an antenna is close to the tumor location, which the coordinate of maximum SAR is approximated the tumor location. For reliable, we experiment by random tumor location to 3 position in the same size of tumor and simulation the result again by varying the antenna position in 5 position again, and it also detectable the tumor position from the antenna that nearby tumor position by maximum value of SAR, which it can be detected the tumor with precision in all frequency between 4-8 GHz. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=specific%20absorption%20rate%20%28SAR%29" title="specific absorption rate (SAR)">specific absorption rate (SAR)</a>, <a href="https://publications.waset.org/abstracts/search?q=ultra%20wideband%20%28UWB%29" title=" ultra wideband (UWB)"> ultra wideband (UWB)</a>, <a href="https://publications.waset.org/abstracts/search?q=coordinates" title=" coordinates"> coordinates</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20detection" title=" cancer detection"> cancer detection</a> </p> <a href="https://publications.waset.org/abstracts/10465/ultra-wideband-breast-cancer-detection-by-using-sar-for-indication-the-tumor-location" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/10465.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">403</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5225</span> Identification of Functional T Cell Receptors Reactive to Tumor Antigens from the T Cell Repertoire of Healthy Donors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Isaac%20Quiros-Fernandez">Isaac Quiros-Fernandez</a>, <a href="https://publications.waset.org/abstracts/search?q=Angel%20Cid-Arregui"> Angel Cid-Arregui</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor-reactive T cell receptors (TCRs) are being subject of intense investigation since they offer great potential in adoptive cell therapies against cancer. However, the identification of tumor-specific TCRs has proven challenging, for instance, due to the limited expansion capacity of tumor-infiltrating T cells (TILs) and the extremely low frequencies of tumor-reactive T cells in the repertoire of patients and healthy donors. We have developed an approach for rapid identification and characterization of neoepitope-reactive TCRs from the T cell repertoire of healthy donors. CD8 T cells isolated from multiple donors are subjected to a first sorting step after staining with HLA multimers carrying the peptide of interest. The isolated cells are expanded for two weeks, after which a second sorting is performed using the same peptide-HLA multimers. The cells isolated in this way are then processed for single-cell sequencing of their TCR alpha and beta chains. Newly identified TCRs are cloned in appropriate expression vectors for functional analysis on Jurkat, NK92, and primary CD8 T cells and tumor cells expressing the appropriate antigen. We have identified TCRs specifically binding HLA-A2 presenting epitopes of tumor antigens, which are capable of inducing TCR-mediated cell activation and cytotoxicity in target cancer cell lines. This method allows the identification of tumor-reactive TCRs in about two to three weeks, starting from peripheral blood samples of readily available healthy donors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=TCR" title=" TCR"> TCR</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20antigens" title=" tumor antigens"> tumor antigens</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotherapy" title=" immunotherapy"> immunotherapy</a> </p> <a href="https://publications.waset.org/abstracts/153990/identification-of-functional-t-cell-receptors-reactive-to-tumor-antigens-from-the-t-cell-repertoire-of-healthy-donors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153990.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">69</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5224</span> Ancelim: Health System Restoration Protocol for Cancer Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mark%20Berry">Mark Berry</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A number of studies have identified several factors involved in the malignant progression of cancer cells. The Primary modulator in driving inflammation to these transformed cells has been identified as the transcription factor known as nuclear factor-κB. This essential regulator of inflammation and the development of cancer, combined with a microenvironment of inflammation and signaling molecules, plays a major role in the malignant progression of cancer, and this progression is the result of the mutagenic predisposition of persistent substances that combat infection at tumor sites and other areas of chronic inflammation. Inflammation-induced tumors, and their inflammatory cells and regulators may be the primary source of metastasis of tumor cells through angiogenesis. Previous research on cytokines and chemokines, including their downstream targets, has been the focus of the cancer/inflammation connection. The identification of the biological mechanisms of other proteins vital to the inflammation cascade and their interactions are crucial to novel and effective therapeutic protocols for the treatment of inflammation-induced cancers. The Ancelim HSRP Protocol is just such a therapeutic intervention. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ancelim" title="ancelim">ancelim</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=inflammation" title=" inflammation"> inflammation</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/37512/ancelim-health-system-restoration-protocol-for-cancer-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37512.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">545</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5223</span> The Role of Surgery to Remove the Primary Tumor in Patients with Metastatic Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=A.%20D.%20Zikiryahodjaev">A. D. Zikiryahodjaev</a>, <a href="https://publications.waset.org/abstracts/search?q=L.%20V.%20Bolotina"> L. V. Bolotina</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Sukhotko"> A. S. Sukhotko</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose. To evaluate the expediency and timeliness of performance of surgical treatment as a component of multi-therapy treatment of patients with stage IV breast cancers. Materials and Methods. This investigation comparatively analyzed the results of complex treatment with or without surgery in patients with metastatic breast cancer. We analyzed retrospectively treatment experience of 196 patients with generalized breast cancer in the department of oncology and breast reconstructive surgery of P.A. Herzen Moscow Cancer Research Institute from 2000 to 2012. The average age was (58±1,1) years. Invasive ductul carcinoma was verified in128 patients (65,3%), invasive lobular carcinoma-33 (16,8%), complex form - 19 (9,7%). Complex palliative care involving drug and radiation therapies was performed in two patient groups. The first group includes 124 patients who underwent surgical intervention as complex treatment, the second group includes 72 patients with only medical therapy. Standard systemic therapy was given to all patients. Results. Overall, 3-and 5-year survival in fist group was 43,8 and 21%, in second - 15,1 and 9,3% respectively [p=0,00002 log-rank]. Median survival in patients with surgical treatment composed 32 months, in patients with only systemic therapy-21. The factors having influencing an influence on the prognosis and the quality of life outcomes for of patients with generalized breast cancer were are also studied: hormone-dependent tumor, Her2/neu hyper-expression, reproductive function status (age, menopause existence). Conclusion.Removing primary breast tumor in patients with generalized breast cancer improve long-term outcomes. Three- and five-year survival increased by 28,7 and 16,3% respectively, and median survival–for 11 months. These patients may benefit from resection of the breast tumor. One explanation for the effect of this resection is that reducing the tumor load influences metastatic growth. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=combination%20therapy" title=" combination therapy"> combination therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=factors%20of%20prognosis" title=" factors of prognosis"> factors of prognosis</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20tumor" title=" primary tumor"> primary tumor</a> </p> <a href="https://publications.waset.org/abstracts/20501/the-role-of-surgery-to-remove-the-primary-tumor-in-patients-with-metastatic-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20501.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">416</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5222</span> Zinc Oxide Nanoparticles as Support for Classical Anti-cancer Therapies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nadine%20Wiesmann">Nadine Wiesmann</a>, <a href="https://publications.waset.org/abstracts/search?q=Melanie%20Viel"> Melanie Viel</a>, <a href="https://publications.waset.org/abstracts/search?q=Christoph%20Buhr"> Christoph Buhr</a>, <a href="https://publications.waset.org/abstracts/search?q=Rachel%20Tanner"> Rachel Tanner</a>, <a href="https://publications.waset.org/abstracts/search?q=Wolfgang%20Tremel"> Wolfgang Tremel</a>, <a href="https://publications.waset.org/abstracts/search?q=Juergen%20Brieger"> Juergen Brieger</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Recidivation of tumors and the development of resistances against the classical anti-tumor approaches represent a major challenge we face when treating cancer. In order to master this challenge, we are in desperate need of new treatment options beyond the beaten tracks. Zinc oxide nanoparticles (ZnO NPs) represent such an innovative approach. Zinc oxide is characterized by a high level of biocompatibility, concurrently ZnO NPs are able to exert anti-tumor effects. By concentration of the nanoparticles at the tumor site, tumor cells can specifically be exposed to the nanoparticles while low zinc concentrations at off-target sites are tolerated well and can be excreted easily. We evaluated the toxicity of ZnO NPs in vitro with the help of immortalized tumor cell lines and primary cells stemming from healthy tissue. Additionally, the Chorioallantoic Membrane Assay (CAM Assay) was employed to gain insights into the in vivo behavior of the nanoparticles. We could show that ZnO NPs interact with tumor cells as nanoparticulate matter. Furthermore, the extensive release of zinc ions from the nanoparticles nearby and within the tumor cells results in overload with zinc. Beyond that, ZnO NPs were found to further the generation of reactive oxygen species (ROS). We were able to show that tumor cells were more prone to the toxic effects of ZnO NPs at intermediate concentrations compared to fibroblasts. With the help of ZnO NPs covered by a silica shell in which FITC dye was incorporated, we were able to track ZnO NPs within tumor cells as well as within a whole organism in the CAM assay after injection into the bloodstream. Depending on the applied concentrations, selective tumor cell killing seems feasible. Furthermore, the combinational treatment of tumor cells with radiotherapy and ZnO NPs shows promising results. Still, further investigations are needed to gain a better understanding of the interaction between ZnO NPs and the human body to be able to pave the way for their application as an innovative anti-tumor agent in the clinics. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=metal%20oxide%20nanoparticles" title="metal oxide nanoparticles">metal oxide nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=nanomedicine" title=" nanomedicine"> nanomedicine</a>, <a href="https://publications.waset.org/abstracts/search?q=overcome%20resistances%20against%20classical%20treatment%20options" title=" overcome resistances against classical treatment options"> overcome resistances against classical treatment options</a>, <a href="https://publications.waset.org/abstracts/search?q=zinc%20oxide%20nanoparticles" title=" zinc oxide nanoparticles"> zinc oxide nanoparticles</a> </p> <a href="https://publications.waset.org/abstracts/126048/zinc-oxide-nanoparticles-as-support-for-classical-anti-cancer-therapies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/126048.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">128</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5221</span> Differential Infection of Primary Human B-Cells and EBV Positive B-Lymphoma Cell Lines by Recombinant AAV Serotypes </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Elham%20Ahmadi">Elham Ahmadi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehrdad%20Ravanshad"> Mehrdad Ravanshad</a>, <a href="https://publications.waset.org/abstracts/search?q=Joyce%20Fingeroth"> Joyce Fingeroth</a>, <a href="https://publications.waset.org/abstracts/search?q=Mazyar%20Ziyaeyan"> Mazyar Ziyaeyan</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajesh%20Panigrahi"> Rajesh Panigrahi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jun%20Xie"> Jun Xie</a>, <a href="https://publications.waset.org/abstracts/search?q=Gao%20Guangping"> Gao Guangping</a> </p> <p class="card-text"><strong>Abstract:</strong></p> B-cell proliferative disorders often occur among persons that are T-cell compromised. These disorders are primarily EBV+ and can first present with a focal lesion. Direct introduction of oncolytic viruses into localized tumors provides theoretical advantages over chemotherapy and immunotherapy by reducing systemic toxicity, to which the immunocompromised host is most vulnerable. Widely studied as a vehicle for gene therapy, AAV has only rarely been applied to treat cancer. As a prelude to development of a therapeutic vehicle, we assessed the ability of 15 distinct recombinant AAV serotypes (rAAV1, rAAV2, rAAV3b, rAAV4, rAAV5, rAAV6, rAAV6.2, rAAV6TM, rAAV7, rAAV8, rAAVrh8, rAAV9, rAAVrh10, rAAV39, rAAV43) bearing eGFP to infect human B-cell tumor lines compared with primary B-cells in vitro. Enhanced infection of tumor lines by AAV 6.2 was demonstrated by flow cytometry. EBV superinfection of EBV negative B-cell tumor lines increased susceptibility to AAV6.2 infection. As proof of concept, AAV6.2 bearing HSV-1 thymidine kinase in place of eGFP eliminated tumor cells upon exposure to ganciclovir. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=AAV" title="AAV">AAV</a>, <a href="https://publications.waset.org/abstracts/search?q=gene%20therapy" title=" gene therapy"> gene therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=lymphoma" title=" lymphoma"> lymphoma</a>, <a href="https://publications.waset.org/abstracts/search?q=malignancy" title=" malignancy"> malignancy</a>, <a href="https://publications.waset.org/abstracts/search?q=tropism" title=" tropism"> tropism</a> </p> <a href="https://publications.waset.org/abstracts/112865/differential-infection-of-primary-human-b-cells-and-ebv-positive-b-lymphoma-cell-lines-by-recombinant-aav-serotypes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/112865.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">120</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5220</span> A Rare Case of Synchronous Colon Adenocarcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Shafi%20Bin%20Mahboob%20Ali">Mohamed Shafi Bin Mahboob Ali</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Synchronous tumor is defined as the presence of more than one primary malignant lesion in the same patient at the indexed diagnosis. It is a rare occurrence, especially in the spectrum of colorectal cancer, which accounts for less than 4%. The underlying pathology of a synchronous tumor is thought to be due to a genomic factor, which is microsatellite instability (MIS) with the involvement of BRAF, KRAS, and the GSRM1 gene. There are no specific sites of occurrence for the synchronous colorectal tumor, but many studies have shown that a synchronous tumor has about 43% predominance in the ascending colon with rarity in the sigmoid colon. Case Report: We reported a case of a young lady in the middle of her 30's with no family history of colorectal cancer that was diagnosed with a synchronous adenocarcinoma at the descending colon and rectosigmoid region. The lady's presentation was quite perplexing as she presented to the district hospital initially with simple, uncomplicated hemorrhoids and constipation. She was then referred to our center for further management as she developed a 'football' sized right gluteal swelling with a complete intestinal obstruction and bilateral lower-limb paralysis. We performed a CT scan and biopsy of the lesion, which found that the tumor engulfed the sacrococcygeal region with more than one primary lesion in the colon as well as secondaries in the liver. The patient was operated on after a multidisciplinary meeting was held. Pelvic exenteration with tumor debulking and anterior resection were performed. Postoperatively, she was referred to the oncology team for chemotherapy. She had a tremendous recovery in eight months' time with a partial regain of her lower limb power. The patient is still under our follow-up with an improved quality of life post-intervention. Discussion: Synchronous colon cancer is rare, with an incidence of 2.4% to 12.4%. It has male predominance and is pathologically more advanced compared to a single colon lesion. Down staging the disease by means of chemoradiotherapy has shown to be effective in managing this tumor. It is seen commonly on the right colon, but in our case, we found it on the left colon and the rectosigmoid. Conclusion: Managing a synchronous colon tumor could be challenging to surgeons, especially in deciding the extent of resection and postoperative functional outcomes of the bowel; thus, individual treatment strategies are needed to tackle this pathology. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=synchronous" title="synchronous">synchronous</a>, <a href="https://publications.waset.org/abstracts/search?q=colon" title=" colon"> colon</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma" title=" adenocarcinoma"> adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/161402/a-rare-case-of-synchronous-colon-adenocarcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/161402.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">108</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5219</span> Determination of Circulating Tumor Cells in Breast Cancer Patients by Electrochemical Biosensor</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=G%C3%B6k%C3%A7e%20Erdemir">Gökçe Erdemir</a>, <a href="https://publications.waset.org/abstracts/search?q=%C4%B0lhan%20Yayl%C4%B1m"> İlhan Yaylım</a>, <a href="https://publications.waset.org/abstracts/search?q=Serap%20Erdem-Kuruca"> Serap Erdem-Kuruca</a>, <a href="https://publications.waset.org/abstracts/search?q=Musa%20Mutlu%20Can"> Musa Mutlu Can</a> </p> <p class="card-text"><strong>Abstract:</strong></p> It has been determined that the main reason for the death of cancer disease is caused by metastases rather than the primary tumor. The cells that leave the primary tumor and enter the circulation and cause metastasis in the secondary organs are called "circulating tumor cells" (CTCs). The presence and number of circulating tumor cells has been associated with poor prognosis in many major types of cancer, including breast, prostate, and colorectal cancer. It is thought that knowledge of circulating tumor cells, which are seen as the main cause of cancer-related deaths due to metastasis, plays a key role in the diagnosis and treatment of cancer. The fact that tissue biopsies used in cancer diagnosis and follow-up are an invasive method and are insufficient in understanding the risk of metastasis and the progression of the disease have led to new searches. Liquid biopsy tests performed with a small amount of blood sample taken from the patient for the detection of CTCs are easy and reliable, as well as allowing more than one sample to be taken over time to follow the prognosis. However, since these cells are found in very small amounts in the blood, it is very difficult to capture them and specially designed analytical techniques and devices are required. Methods based on the biological and physical properties of the cells are used to capture these cells in the blood. Early diagnosis is very important in following the prognosis of tumors of epithelial origin such as breast, lung, colon and prostate. Molecules such as EpCAM, vimentin, and cytokeratins are expressed on the surface of cells that pass into the circulation from very few primary tumors and reach secondary organs from the circulation, and are used in the diagnosis of cancer in the early stage. For example, increased EpCAM expression in breast and prostate cancer has been associated with prognosis. These molecules can be determined in some blood or body fluids to be taken from patients. However, more sensitive methods are required to be able to determine when they are at a low level according to the course of the disease. The aim is to detect these molecules found in very few cancer cells with the help of sensitive, fast-sensing biosensors, first in breast cancer cells reproduced in vitro and then in blood samples taken from breast cancer patients. In this way, cancer cells can be diagnosed early and easily and effectively treated. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=electrochemical%20biosensors" title="electrochemical biosensors">electrochemical biosensors</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=circulating%20tumor%20cells" title=" circulating tumor cells"> circulating tumor cells</a>, <a href="https://publications.waset.org/abstracts/search?q=EpCAM" title=" EpCAM"> EpCAM</a>, <a href="https://publications.waset.org/abstracts/search?q=Vimentin" title=" Vimentin"> Vimentin</a>, <a href="https://publications.waset.org/abstracts/search?q=Cytokeratins" title=" Cytokeratins"> Cytokeratins</a> </p> <a href="https://publications.waset.org/abstracts/140961/determination-of-circulating-tumor-cells-in-breast-cancer-patients-by-electrochemical-biosensor" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140961.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">261</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5218</span> Evaluation of Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Correlation with Molecular Subtypes and Clinicopathological Parameters</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arundhathi%20S.">Arundhathi S.</a>, <a href="https://publications.waset.org/abstracts/search?q=Poongodi%20R."> Poongodi R.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor-infiltrating lymphocytes (TILs) are indicative of the local immune response against tumor proliferation and metastasis. Emerging as a significant marker of immune reactivity, TILs are utilized to evaluate prognostic outcomes across various malignancies, including colon, ovarian, lung, bladder, and breast cancers. In breast cancer (BC), TILs are particularly relevant for assessing tumor response to therapy in both adjuvant and neoadjuvant settings, with a prominent role in triple-negative breast cancer (TNBC), where they have been associated with improved outcomes. As such, TILs are recognized as an independent marker of favorable prognosis in several tumor types, underscoring their potential as a tool in personalized cancer therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=intratumoral%20TIL" title=" intratumoral TIL"> intratumoral TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=stromal%20TIL" title=" stromal TIL"> stromal TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20infiltrating%20lymphocytes" title=" tumor infiltrating lymphocytes"> tumor infiltrating lymphocytes</a> </p> <a href="https://publications.waset.org/abstracts/194529/evaluation-of-tumor-infiltrating-lymphocytes-in-breast-carcinoma-correlation-with-molecular-subtypes-and-clinicopathological-parameters" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/194529.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">8</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5217</span> MicroRNA Expression Distinguishes Neutrophil Subtypes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20I.%20You">R. I. You</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20L.%20Ho"> C. L. Ho</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Dai"> M. S. Dai</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20M.%20Hung"> H. M. Hung</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20F.%20Yen"> S. F. Yen</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20S.%20Chen"> C. S. Chen</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20Y.%20Chao"> T. Y. Chao</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Neutrophils are the most abundant innate immune cells to against invading microorganisms. Numerous data shown neutrophils have plasticity in response to physiological and pathological conditions. Tumor-associated neutrophils (TAN) exist in distinct types of tumor and play an important role in cancer biology. Different transcriptomic profiles of neutrophils in tumor and non-tumor samples have been identified. Several miRNAs have been recognized as regulators of gene expression in neutrophil, which may have key roles in neutrophil activation. However, the miRNAs expression patterns in TAN are not well known. To address this question, magnetic bead isolated neutrophils from tumor-bearing mice were used in this study. We analyzed production of reactive oxygen species (ROS) by luminol-dependent chemiluminescence assay. The expression of miRNAs targeting NADPH oxidase, ROS generation and autophagy was explored using quantitative real-time polymerase chain reaction. Our data suggest that tumor environment influence neutrophil develop to differential states of activation via miRNAs regulation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=tumor-associated%20neutrophil" title="tumor-associated neutrophil">tumor-associated neutrophil</a>, <a href="https://publications.waset.org/abstracts/search?q=miRNAs" title=" miRNAs"> miRNAs</a>, <a href="https://publications.waset.org/abstracts/search?q=neutrophil" title=" neutrophil"> neutrophil</a>, <a href="https://publications.waset.org/abstracts/search?q=ROS" title=" ROS "> ROS </a> </p> <a href="https://publications.waset.org/abstracts/13682/microrna-expression-distinguishes-neutrophil-subtypes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13682.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">470</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5216</span> Discriminant Function Based on Circulating Tumor Cells for Accurate Diagnosis of Metastatic Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hatem%20A.%20El-Mezayen">Hatem A. El-Mezayen</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Abdelmajeed"> Ahmed Abdelmajeed</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatehya%20Metwally"> Fatehya Metwally</a>, <a href="https://publications.waset.org/abstracts/search?q=Usama%20Elsaly"> Usama Elsaly</a>, <a href="https://publications.waset.org/abstracts/search?q=Salwa%20Atef"> Salwa Atef</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor metastasis involves the dissemination of malignant cells into the basement membrane and vascular system contributes to the circulating pool of these markers. In this context our aim has been focused on development of a non-invasive. Circulating tumor cells (CTCs) represent a unique liquid biopsy carrying comprehensive biological information of the primary tumor. Herein, we sought to develop a novel score based on the combination of the most significant CTCs biomarkers with and routine laboratory tests for accurate detection of metastatic breast cancer. Methods: Cytokeratin 18 (CK18), Cytokeratin 19 (CK19), and CA15.3 were assayed in metastatic breast cancer (MBC) patients (75), non-MBC patients (50) and healthy control (20). Results: Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named MBC-CTCs = CA15.3 (U/L) × 0.08 + CK 18 % × 2.9 + CK19 × 3.1– 510. That function correctly classified 87% of metastatic breast cancer at cut-off value = 0.55. (i.e great than 0.55 indicates patients with metastatic breast cancer and less than 0.55 indicates patients with non-metastatic breast cancer). Conclusion: MBC-CTCs is a novel, non-invasive and simple can applied to discriminate patients with metastatic breast cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=metastatic%20breast%20cancer" title="metastatic breast cancer">metastatic breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=circulating%20tumor%20cells" title=" circulating tumor cells"> circulating tumor cells</a>, <a href="https://publications.waset.org/abstracts/search?q=cytokeratin" title=" cytokeratin"> cytokeratin</a>, <a href="https://publications.waset.org/abstracts/search?q=EpiCam" title=" EpiCam"> EpiCam</a> </p> <a href="https://publications.waset.org/abstracts/146716/discriminant-function-based-on-circulating-tumor-cells-for-accurate-diagnosis-of-metastatic-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146716.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">214</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5215</span> Recent Advancement in Dendrimer Based Nanotechnology for the Treatment of Brain Tumor</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nitin%20Dwivedi">Nitin Dwivedi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jigna%20Shah"> Jigna Shah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Brain tumor is metastatic neoplasm of central nervous system, in most of cases it is life threatening disease with low survival rate. Despite of enormous efforts in the development of therapeutics and diagnostic tools, the treatment of brain tumors and gliomas remain a considerable challenge in the area of neuro-oncology. The most reason behind of this the presence of physiological barriers including blood brain barrier and blood brain tumor barrier, lead to insufficient reach ability of therapeutic agents at the site of tumor, result of inadequate destruction of gliomas. So there is an indeed need empowerment of brain tumor imaging for better characterization and delineation of tumors, visualization of malignant tissue during surgery, and tracking of response to chemotherapy and radiotherapy. Multifunctional different generations of dendrimer offer an improved effort for potentiate drug delivery at the site of brain tumor and gliomas. So this article emphasizes the innovative dendrimer approaches in tumor targeting, tumor imaging and delivery of therapeutic agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=blood%20brain%20barrier" title="blood brain barrier">blood brain barrier</a>, <a href="https://publications.waset.org/abstracts/search?q=dendrimer" title=" dendrimer"> dendrimer</a>, <a href="https://publications.waset.org/abstracts/search?q=gliomas" title=" gliomas"> gliomas</a>, <a href="https://publications.waset.org/abstracts/search?q=nanotechnology" title=" nanotechnology"> nanotechnology</a> </p> <a href="https://publications.waset.org/abstracts/30047/recent-advancement-in-dendrimer-based-nanotechnology-for-the-treatment-of-brain-tumor" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30047.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">561</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5214</span> Computer Aided Diagnostic System for Detection and Classification of a Brain Tumor through MRI Using Level Set Based Segmentation Technique and ANN Classifier</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Atanu%20K%20Samanta">Atanu K Samanta</a>, <a href="https://publications.waset.org/abstracts/search?q=Asim%20Ali%20Khan"> Asim Ali Khan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Due to the acquisition of huge amounts of brain tumor magnetic resonance images (MRI) in clinics, it is very difficult for radiologists to manually interpret and segment these images within a reasonable span of time. Computer-aided diagnosis (CAD) systems can enhance the diagnostic capabilities of radiologists and reduce the time required for accurate diagnosis. An intelligent computer-aided technique for automatic detection of a brain tumor through MRI is presented in this paper. The technique uses the following computational methods; the Level Set for segmentation of a brain tumor from other brain parts, extraction of features from this segmented tumor portion using gray level co-occurrence Matrix (GLCM), and the Artificial Neural Network (ANN) to classify brain tumor images according to their respective types. The entire work is carried out on 50 images having five types of brain tumor. The overall classification accuracy using this method is found to be 98% which is significantly good. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=brain%20tumor" title="brain tumor">brain tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=computer-aided%20diagnostic%20%28CAD%29%20system" title=" computer-aided diagnostic (CAD) system"> computer-aided diagnostic (CAD) system</a>, <a href="https://publications.waset.org/abstracts/search?q=gray-level%20co-occurrence%20matrix%20%28GLCM%29" title=" gray-level co-occurrence matrix (GLCM)"> gray-level co-occurrence matrix (GLCM)</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20segmentation" title=" tumor segmentation"> tumor segmentation</a>, <a href="https://publications.waset.org/abstracts/search?q=level%20set%20method" title=" level set method"> level set method</a> </p> <a href="https://publications.waset.org/abstracts/61237/computer-aided-diagnostic-system-for-detection-and-classification-of-a-brain-tumor-through-mri-using-level-set-based-segmentation-technique-and-ann-classifier" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/61237.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">511</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5213</span> Psychological Aspects of Quality of Life in Patients with Primary and Metastatic Bone Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=O.%20Yu%20Shchelkova">O. Yu Shchelkova</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20B.%20Usmanova"> E. B. Usmanova</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Last decades scientific research of quality of life (QoL) is developing fast worldwide. QoL concept pays attention to emotional experience of disease in patients, particularly to personal sense of possibility to satisfy actual needs and possibility of full social functioning in spite of disease limitations. QoL in oncological patients is studied intensively. Nevertheless, the issue of QoL in patients with bone tumors focused on psychological factors of QoL and relation to disease impact on QoL is not discussed. The aim of the study was to reveal the basic aspects and personality factors of QoL in patients with bone tumor. Results: Study participants were 139 patients with bone tumors. The diagnoses were osteosarcoma (n=42), giant cell tumor (n=32), chondrosarcoma (n=32), Ewing sarcoma (n=10) and bone metastases (n=23). The study revealed that patients with bone metastases assess their health significantly worse than other patients. Besides patients with osteosarcoma evaluate their general health higher than patients with giant cell tumors. Social functioning in patients with chondrosarcoma is higher than in patients with bone metastases and patients with giant cell tumor. Patients with chondrosarcoma have higher physical functioning and less restricted in daily activities than patients with bone metastases. Patients with bone metastases characterize their pain as more widespread than patients with primary bone tumors and have more functional restrictions due to bone incision. Moreover, the study revealed personality significant influence on QoL related to bone tumors. Such characteristics in structure of personality as high degree of self-consciousness, personal resources, cooperation and disposition to positive reappraisal in difficult situation correspond to higher QoL. Otherwise low personal resources and slight problem solving behaviour, low degree of self-consciousness and high social dependence correspond to decrease of QoL in patients with bone tumors. Conclusion: Patients with bone metastasis have lower QoL compared to patients with primary bone tumors. Patients with giant cell tumor have the worth quality of life among patients with primary bone tumors. Furthermore, the results revealed differences in QoL parameters associated with personality characteristics in patients with bone tumors. Such psychological factors as future goals, interest in life and emotional saturation, besides high degree of personal resources and cooperation influence on increasing QoL in patients with bone tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=quality%20of%20life" title="quality of life">quality of life</a>, <a href="https://publications.waset.org/abstracts/search?q=psychological%20factors" title=" psychological factors"> psychological factors</a>, <a href="https://publications.waset.org/abstracts/search?q=bone%20tumor" title=" bone tumor"> bone tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=personality" title=" personality"> personality</a> </p> <a href="https://publications.waset.org/abstracts/94047/psychological-aspects-of-quality-of-life-in-patients-with-primary-and-metastatic-bone-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/94047.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">140</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5212</span> Mage Fusion Based Eye Tumor Detection</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Ashit">Ahmed Ashit</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Image fusion is a significant and efficient image processing method used for detecting different types of tumors. This method has been used as an effective combination technique for obtaining high quality images that combine anatomy and physiology of an organ. It is the main key in the huge biomedical machines for diagnosing cancer such as PET-CT machine. This thesis aims to develop an image analysis system for the detection of the eye tumor. Different image processing methods are used to extract the tumor and then mark it on the original image. The images are first smoothed using median filtering. The background of the image is subtracted, to be then added to the original, results in a brighter area of interest or tumor area. The images are adjusted in order to increase the intensity of their pixels which lead to clearer and brighter images. once the images are enhanced, the edges of the images are detected using canny operators results in a segmented image comprises only of the pupil and the tumor for the abnormal images, and the pupil only for the normal images that have no tumor. The images of normal and abnormal images are collected from two sources: “Miles Research” and “Eye Cancer”. The computerized experimental results show that the developed image fusion based eye tumor detection system is capable of detecting the eye tumor and segment it to be superimposed on the original image. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=image%20fusion" title="image fusion">image fusion</a>, <a href="https://publications.waset.org/abstracts/search?q=eye%20tumor" title=" eye tumor"> eye tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=canny%20operators" title=" canny operators"> canny operators</a>, <a href="https://publications.waset.org/abstracts/search?q=superimposed" title=" superimposed"> superimposed</a> </p> <a href="https://publications.waset.org/abstracts/30750/mage-fusion-based-eye-tumor-detection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30750.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">363</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5211</span> Effects of Aerobic Training on MicroRNA Let-7a Expression and Levels of Tumor Tissue IL-6 in Mice With Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Leila%20Anoosheh">Leila Anoosheh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Aim: The aim of this study was to assess The effects of aerobic training on microRNA let-7a expression and levels of tumor tissue IL-6 in mice with breast cancer. Method: Twenty BALB/c c mice (4-5 weeks,17 gr mass) were cancerous by injection of estrogen-dependent receptor breast cancer cells MC4-L2 and divided into two groups: tumor-training(TT) and tumor-control(TC) group. Then TT group completed aerobic training for 6 weeks, 5 days per week (14-18 m/min). After tumor emersion, tumor width and length were measured by digital caliper every week. 48 hours after the last exercise subjects were killed. Tissue sampling were collected and stored in -70ᵒ. Tumor tissue was homogenized and let-7a expression and IL-6 levels were accounted with Real time-PCR and ELISA Kit respectively. Statistical analysis of let-7a was conducted by the REST software. Repeated measures and independent tests were used to assess tumor size and IL-6, respectively. Results: Tumor size and IL-6 levels were significantly decreased in TT group compare with TC group (p<0.05). microRNA let-7a was increased significantly in TT against control group respectively (p=0/000). Conclusion: Reduction in tumor size, followed by aerobic exercise can be attributed to the loss of inflammatory factors such as IL-6; It seems that regarding to up regulation effects of aerobic exercise training on let-7a and down regulation effects of that on IL-6 in mice with breast cancer, This type of training can be used as adjuvant therapy in conjunction with other therapies for breast cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=aerobic%20training" title=" aerobic training"> aerobic training</a>, <a href="https://publications.waset.org/abstracts/search?q=microRNA%20%20let-7a" title=" microRNA let-7a"> microRNA let-7a</a>, <a href="https://publications.waset.org/abstracts/search?q=IL-6" title=" IL-6"> IL-6</a> </p> <a href="https://publications.waset.org/abstracts/16519/effects-of-aerobic-training-on-microrna-let-7a-expression-and-levels-of-tumor-tissue-il-6-in-mice-with-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16519.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">431</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5210</span> ESDN Expression in the Tumor Microenvironment Coordinates Melanoma Progression</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Roberto%20Coppo">Roberto Coppo</a>, <a href="https://publications.waset.org/abstracts/search?q=Francesca%20Orso"> Francesca Orso</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniela%20Dettori"> Daniela Dettori</a>, <a href="https://publications.waset.org/abstracts/search?q=Elena%20Quaglino"> Elena Quaglino</a>, <a href="https://publications.waset.org/abstracts/search?q=Lei%20Nie"> Lei Nie</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehran%20M.%20Sadeghi"> Mehran M. Sadeghi</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniela%20Taverna"> Daniela Taverna</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Malignant melanoma is currently the fifth most common cancer in the white population and it is fatal in its metastatic stage. Several research studies in recent years have provided evidence that cancer initiation and progression are driven by genetic alterations of the tumor and paracrine interactions between tumor and microenvironment. Scattered data show that the Endothelial and Smooth muscle cell-Derived Neuropilin-like molecule (ESDN) controls cell proliferation and movement of stroma and tumor cells. To investigate the role of ESDN in the tumor microenvironment during melanoma progression, murine melanoma cells (B16 or B16-F10) were injected in ESDN knockout mice in order to evaluate how the absence of ESDN in stromal cells could influence melanoma progression. While no effect was found on primary tumor growth, increased cell extravasation and lung metastasis formation was observed in ESDN knockout mice compared to wild type controls. In order to understand how cancer cells cross the endothelial barrier during metastatic dissemination in an ESDN-null microenvironment, structure, and permeability of lung blood vessels were analyzed. Interestingly, ESDN knockout mice showed structurally altered and more permeable vessels compared to wild type animals. Since cell surface molecules mediate the process of tumor cell extravasation, the expression of a panel of extravasation-related ligands and receptors was analyzed. Importantly, modulations of N-cadherin, E-selectin, ICAM-1 and VAP-1 were observed in ESDN knockout endothelial cells, suggesting the presence of a favorable tumor microenvironment which facilitates melanoma cell extravasation and metastasis formation in the absence of ESDN. Furthermore, a potential contribution of immune cells in tumor dissemination was investigated. An increased recruitment of macrophages in the lungs of ESDN knockout mice carrying subcutaneous B16-F10 tumors was found. In conclusion, our data suggest a functional role of ESDN in the tumor microenvironment during melanoma progression and the identification of the mechanisms that regulate tumor cell extravasation could lead to the development of new therapies to reduce metastasis formation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=melanoma" title="melanoma">melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20microenvironment" title=" tumor microenvironment"> tumor microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=extravasation" title=" extravasation"> extravasation</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20surface%20molecules" title=" cell surface molecules"> cell surface molecules</a> </p> <a href="https://publications.waset.org/abstracts/44830/esdn-expression-in-the-tumor-microenvironment-coordinates-melanoma-progression" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/44830.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">333</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5209</span> An Insight into Early Stage Detection of Malignant Tumor by Microwave Imaging </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Hassan%20Khalil">Muhammad Hassan Khalil</a>, <a href="https://publications.waset.org/abstracts/search?q=Xu%20Jiadong"> Xu Jiadong</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Detection of malignant tumor inside the breast of women is a challenging field for the researchers. MWI (Microwave imaging) for breast cancer diagnosis has been of interest for last two decades, newly it suggested for finding cancerous tissues of women breast. A simple and basic idea of the mathematical modeling is used throughout this paper for imaging of malignant tumor. In this paper, the authors explained inverse scattering method in the microwave imaging and also present some simulation results. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer%20detection" title="breast cancer detection">breast cancer detection</a>, <a href="https://publications.waset.org/abstracts/search?q=microwave%20imaging" title=" microwave imaging"> microwave imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=tomography" title=" tomography"> tomography</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/2718/an-insight-into-early-stage-detection-of-malignant-tumor-by-microwave-imaging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/2718.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">410</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5208</span> Liver Tumor Detection by Classification through FD Enhancement of CT Image</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20Ghatwary">N. Ghatwary</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ahmed"> A. Ahmed</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Jalab"> H. Jalab</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this paper, an approach for the liver tumor detection in computed tomography (CT) images is represented. The detection process is based on classifying the features of target liver cell to either tumor or non-tumor. Fractional differential (FD) is applied for enhancement of Liver CT images, with the aim of enhancing texture and edge features. Later on, a fusion method is applied to merge between the various enhanced images and produce a variety of feature improvement, which will increase the accuracy of classification. Each image is divided into NxN non-overlapping blocks, to extract the desired features. Support vector machines (SVM) classifier is trained later on a supplied dataset different from the tested one. Finally, the block cells are identified whether they are classified as tumor or not. Our approach is validated on a group of patients’ CT liver tumor datasets. The experiment results demonstrated the efficiency of detection in the proposed technique. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=fractional%20differential%20%28FD%29" title="fractional differential (FD)">fractional differential (FD)</a>, <a href="https://publications.waset.org/abstracts/search?q=computed%20tomography%20%28CT%29" title=" computed tomography (CT)"> computed tomography (CT)</a>, <a href="https://publications.waset.org/abstracts/search?q=fusion" title=" fusion"> fusion</a>, <a href="https://publications.waset.org/abstracts/search?q=aplha" title=" aplha"> aplha</a>, <a href="https://publications.waset.org/abstracts/search?q=texture%20features." title=" texture features."> texture features.</a> </p> <a href="https://publications.waset.org/abstracts/39719/liver-tumor-detection-by-classification-through-fd-enhancement-of-ct-image" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/39719.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">358</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5207</span> Stability Analysis of Tumor-Immune Fractional Order Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sadia%20Arshad">Sadia Arshad</a>, <a href="https://publications.waset.org/abstracts/search?q=Yifa%20Tang"> Yifa Tang</a>, <a href="https://publications.waset.org/abstracts/search?q=Dumitru%20Baleanu"> Dumitru Baleanu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A fractional order mathematical model is proposed that incorporate CD8+ cells, natural killer cells, cytokines and tumor cells. The tumor cells growth in the absence of an immune response is modeled by logistic law as it was the simplest form for which predictions also agreed with the experimental data. Natural Killer Cells are our first line of defense. NK cells directly kill tumor cells through several mechanisms, including the release of cytoplasmic granules containing perforin and granzyme, expression of tumor necrosis factor (TNF) family members. The effect of the NK cells on the tumor cell population is expressed with the product term. Rational form is used to describe interaction between CD8+ cells and tumor cells. A number of cytokines are produced by NKs, including tumor necrosis factor TNF, IFN, and interleukin (IL-10). Source term for cytokines is modeled by Michaelis-Menten form to indicate the saturated effects of the immune response. Stability of the equilibrium points is discussed for biologically significant values of bifurcation parameters. We studied the treatment of fractional order system by investigating analytical conditions of tumor eradication. Numerical simulations are presented to illustrate the analytical results. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer%20model" title="cancer model">cancer model</a>, <a href="https://publications.waset.org/abstracts/search?q=fractional%20calculus" title=" fractional calculus"> fractional calculus</a>, <a href="https://publications.waset.org/abstracts/search?q=numerical%20simulations" title=" numerical simulations"> numerical simulations</a>, <a href="https://publications.waset.org/abstracts/search?q=stability%20analysis" title=" stability analysis"> stability analysis</a> </p> <a href="https://publications.waset.org/abstracts/52821/stability-analysis-of-tumor-immune-fractional-order-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/52821.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">315</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=174">174</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=175">175</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=primary%20tumor&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>